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p53 is one of the most studied tumor suppressors in the cancer research ﬁeld. Of note, over 50% of human tumors carry loss of
functionmutations,andthusp53hasbeen considered to be aclassicalKnudson-type tumorsuppressor.From thefunctionalpoint
of view, p53 is a nuclear transcription factor to transactivate a variety of its target genes implicated in the induction of cell cycle
arrest, DNA repair, and apoptotic cell death. In response to cellular stresses such as DNA damage, p53 is activated and promotes
cell cycle arrest followed by the replacement of DNA lesions and/or apoptotic cell death. Therefore, p53 is able to maintain the
genomic integrity to prevent the accumulation of genetic alterations, and thus stands at a crossroad between cell survival and cell
death. In this paper, we describe a variety of molecular mechanisms behind the regulation of p53.
1.Introduction
p53 has been initially identiﬁed in crude cell lysates prepared
from cells transformed by simian virus 40 (SV40) [1–5].
Subsequent studies demonstrated that p53 forms a stable
complex in SV40-transfromed cells with SV40 large T anti-
gen which has an oncogenic potential, and p53 had an ability
to promote tumor growth. In support with these results, p53
was detectable in a variety of tumor-derived cell lines [1, 3,
4]. Based on these observations, p53 came to be classiﬁed as
an oncogene [6]. However, this classical point of view has
been challenged by the ﬁndings showing that the initially
discovered p53 is a mutant form of p53 [7]. In a sharp
contrast to mutant forms of p53,subsequent studies revealed
that wild-type p53 is capable to suppress the malignant
growth of transformed cells as well as tumors, suggesting
that p53 acts as a tumor suppressor [8–12]. Intriguingly, p53
gene locates on the short arm of human chromosome 17
(17p13), where loss of heterozygosity (LOH) was detectable
in a wide variety of tumor tissues. It is worth noting that the
remaining nondeleting p53 allele is mutated in some cases
[13–18].Extensivemutationsearchesdemonstratedthatover
50% of human tumors carry p53 mutations. Indeed, p53-
deﬁcient mice developed spontaneous tumors at a relatively
young age [19].
Ninety-ﬁve percent of the mutations were detected
within the central sequence-speciﬁc DNA-binding region
of p53 [20–22]. These mutations disrupted the whole
conformationofthesequence-speciﬁcDNA-bindingdomain
of p53 and resulted in the loss of its sequence-speciﬁc DNA-
binding ability [23]. Since p53 was a nuclear sequence-
speciﬁc transcription factor which transactivated a set of
its target genes involved in the induction of cell cycle
arrest and/or apoptotic cell death, mutant forms of p53
lacked their critical function to maintain the genomic
integrity. Furthermore, mutant forms of p53 has acquired
a much longer half-life as compared with that of wild-type
p53 [24, 25] and displayed a dominant-negative behavior
toward wild-typep53[26,27].Thisdominant-negative eﬀect
of mutant p53 on wild-type p53 might be mediated by
the hetero-oligomerization through their oligomerization
domains [7, 28–30]. In this connection, p53 mutation
conferred the resistance of tumor cells to anticancer drugs
by inhibiting p53-dependent proapoptotic pathway [31–33].2 Journal of Biomedicine and Biotechnology
Thus, the development of the novel devices to remove or
suppress the dominant-negative eﬀe c to fm u t a n tf o r m so f
p53 on wild-type p53 will serve as a basis for providing
new therapeutic strategies to treat tumors bearing p53
mutations.
As described above, p53 had a strong proapoptotic
activity. Under normal conditions, the expression level of
this dangerous protein is kept at extremely low level. In
response tomultiplecellularstresses includingDNAdamage,
oncogene activation, hypoxia, nucleotide imbalance, and
oxidative damage, p53 was rapidly accumulated in cell
nucleus through chemical modiﬁcations such as phos-
phorylation and acetylation and exerted its proapoptotic
function to remove cells with seriously damaged DNA in
which DNA damage was severe and repair was impossible
[22, 34–36]. In this case, p53 transactivated proapoptotic
target genes including BAX, PUMA, NOXA, and p53AIP1,
and the collaboration of these gene products contributed
to the disruption of mitochondrial membrane potential,
which was a critical step in p53-dependent proapop-
totic pathway [37]. On the other hand, p53 promoted
G1 cell cycle arrest in the early stage of DNA damage
response through the transactivation of p21WAF1, p53R2,
and GADD45 implicated in the induction of cell cycle
arrest and DNA repair [37]. After DNA repair had been
completed, cells reentered into normal cell cycle. Upon DNA
damage, cells underwent either cell cycle arrest or apoptotic
cell death to allow DNA repair or suicide of cells, which
was dependent on the degree and/or the nature of DNA
damage.
For a long time, p53 has been considered to be a
solitary gene product. Due to the improvement of cloning
technologies, Kaghad et al. identiﬁed the ﬁrst p53 homolog
termed p73 [38]. Additionally, Yang et al. discovered the
second p53 homolog termed p63 [39]. Cell-based studies
demonstrated that p73 and p63 act as nuclear sequence-
speciﬁctranscriptionfactorswhichtransactivate theoverlap-
pingset of p53-target genes andalso have an abilitytoinduce
cell cycle arrest and/or apoptotic cell death in cancerous cells
[40, 41]. Like p53, p73, and p63 were induced in response to
a certainsubset ofDNA-damagingagents[42, 43]. Thus, p53
becomesafoundingmemberofp53tumorsuppressorfamily
composed of p53, p73 and p63.
Based on the above-mentioned brief background of p53,
we focus primarily on a variety of regulatory mechanisms of
p53 in the present paper.
2.GeneralFeatureofp53
p53 locates at a short arm of human chromosome 17p13
containing 11 exons spanning 20kb. p53 acts as a nuclear
sequence-speciﬁc transcription factor composed of NH2-
terminal transactivation domain (TA, amino acid residues
1–45), central sequence-speciﬁc DNA-binding domain
(DB, amino acid residues 102–292), and COOH-terminal
oligomerizationdomain(OD,aminoacidresidues319–359).
In addition to these representative functional domains, p53
contains three nuclear localization signals (NLS, amino acid
residues 305–322, 369–375, and 379–384) recognized by
importin α/β complex [44], a Leu-rich nuclear export signal
(NES, amino acid residues 339–352) recognized by CRM1
(chromosomal region maintenance 1) [44], and a Pro-rich
domain (amino acid residues 63–97). Cytoplasmic retention
of p53 was observed in certain breast cancer-derived cells
expressing the truncated form of importin α, indicating
that importin α plays an essential role in nuclear import
of p53 [45]. Cytoplasmic p53 is nonfunctional. Pro-rich
domain has been shown to be associated with proapoptotic
activity of p53 [46, 47]. Deletion of this Pro-rich region
resulted in a complete loss of proapoptotic activity of p53.
Active form of nuclear p53, which functions as a tetramer,
recognizes and binds to a consensus sequence motif made of
tandem 10bp elements (RRRCWWGYYY: R, G/A; W, A/T;
Y, C/T) separated by 1–13bp found within the promoter
regions of p53-target genes. p53 exerts its proapoptotic
function through the transactivation of its target genes [48,
49]. Genome-wide analysis revealed that there exist over
4,000 putative p53-responsive elements [22]. Although all of
these canonical p53-responsive elements might not always
be functional, identiﬁcation and functional analysis of new
p53-target genes provide novel insights into understanding
the precise molecular mechanisms behind p53-dependent
proapoptotic pathway.
Since the sequence-speciﬁc DNA-binding ability of p53
is tightly linked to its proapoptotic activity [48, 49], the
genomic integrity of p53 gene encoding the sequence-
speciﬁc DNA-binding domain (exons 5–8) is particularly
important. Extensivemutationsearch revealedthatover50%
of human tumors carry p53 mutations [20, 21]. Among
these mutations, 95% of them occurred within the genomic
regionencoding thesequence-speciﬁc DNA-bindingdomain
of p53. These mutations disrupted the proper conformation
of the sequence-speciﬁc DNA-binding domain of p53, and
thus mutant forms of p53 lacked the sequence-speciﬁc
transactivation ability. In contrast to the short-lived wild-
type p53, mutant forms of p53 had a longer half-life [24, 25].
Moreover, mutant forms of p53 exhibited an oncogenic
potential [50]and displayed thedominant-negative behavior
toward wild-type p53 [26, 27], suggesting that mutant
formsofp53attenuatep53-dependentproapoptoticpathway
(Figure 1).
Since the previous mutation search for p53 gene focused
on the genomic region encoding the central core sequence-
speciﬁc DNA-binding domain of p53, it is likely that there
could exist the unidentiﬁed mutations outside the cen-
tral core sequence-speciﬁc DNA-binding domain. Indeed,
Lomax et al. found point mutations (L344P and R337C)
within the COOH-terminal oligomerization domain [51,
52]. Similarly, DiGiammarino et al. reported the presence
of a point mutation (R337H) within the COOH-terminal
oligomerizationdomain[53].Inadditiontothesemutations,
we have found p53ΔC lacking a part of the COOH-terminal
oligomerization domain and nuclear localization signals in
human neuroblastoma-derived cell lines [54]. According to
our results, p53ΔC was largely expressed in cytoplasm and
had a signiﬁcantly lower proapoptotic ability as compared
with wild-type p53. Therefore, p53 mutations detectedJournal of Biomedicine and Biotechnology 3
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Figure 1: Dominant-negative eﬀect of mutant p53 on wild-type
p53. In response to cellular stresses, wild-type p53 is activated and
induces cell cycle arrest and/or apoptotic cell death. Mutant p53
binds to wild-type p53 and inhibits its tumor suppressor function,
thereby promoting tumor formation.
outside central core DNA-binding domain caused loss of
function of p53.
From the clinical point of view, mutational inactivation
of p53 was a frequent and serious molecular event in
most human tumors. Since mutant forms of p53 had
a longer half-life with oncogenic potential, exhibited the
dominant-negative eﬀect on wild-type p53, and thus led to
chemoresistance, it is required to develop novel anticancer
therapeutic approaches to suppress mutant forms of p53
or rescue wild-type p53 activity from mutant p53. In this
regard, a small compound termed PRIMA-1, which has
an ability to reactivate mutant p53, might be one of the
promising and eﬃcient anticancer drugs [55].
3.p53-TargetGene Products
To date, numerous genes have been identiﬁed as p53-target
genes [22, 34–36]. In this section, we would like to describe
the functional signiﬁcances of several representative p53-
target gene products. Since the inductions of cell cycle arrest
and apoptotic cell death are the major roles of p53, p53-
target gene products are closely involved in these cellular
processes.
El-Deiry etal. identiﬁed p53-target genetermed p21WAF1
by using a subtractive hybridization approach [56]. p21WAF1
gene promoter contained a p53-responsive element, and
its gene product had an ability to suppress cell growth.
Alternatively, Harper et al. discovered p21CIP1 as a Cdk2-
(cyclin-dependent kinase 2-) binding partner by employing
a yeast-based two-hybrid procedure [57]. p21CIP1 tightly
bound to Cdk2 and inhibited its protein kinase activity to
block the phosphorylation of pRB. Noda et al. identiﬁed
p21SD1 by using an expression screening from senescent
human diploid ﬁbroblasts [58]. p21SD1 blocked DNA syn-
thesis andmaintained thesenescent phenotype.Surprisingly,
these gene products were identical. Now, we call it p21WAF1.
In response to cellular stresses, p53 induces G1 cell cycle
arrest through the upregulation of p21WAF1.
Tanaka et al. employed a diﬀerential display approach
to isolate a novel p53-inducible gene termed p53R2
whose gene product was highly homologous to ribonu-
cleotide reductase small subunit (R2) [59]. p53R2 was
signiﬁcantly induced in response to DNA damage in
a p53-dependent manner. Intriguingly, p53R2 induced
G2/M arrest and was directly involved in repair of
damaged DNA.
Under normal condition, p53 was kept at an extremely
low level. MDM2 (murine double minute 2), which has
an intrinsic E3 ubiquitin protein ligase activity, controlled
the expression level of p53 by targeting it to ubiquitin-
/proteasome-dependent degradation [60–62]. Barak et al.
described that MDM2 is a direct transcriptional target ofp53
[63]. Thus, MDM2 participates in a negative autoregulatory
feedback loop which controls p53 expression level (see
below).
Among p53-target genes, those that encode mitochon-
drial proteins are particularly attractive, because p53-
dependent apoptosis appears to proceed through mitochon-
d r i a ld y s f u n c t i o n .S e l v a k u m a r a ne ta l .r e p o r t e dt h a tBAX
(Bcl2-associated X protein) is an immediate early p53-
responsive gene [64]. BAX contains two highly conserved
Bcl2 homology 1 and 2 (BH1 and BH2) domains and
displayed a dominant-negative eﬀect over prosurvival Bcl2.
Upon apoptotic stimuli, BAX, which resides on the mito-
chondrial outer membrane, dysregulated the mitochondrial
outer membrane permeability and induced the release of
cytochrome c from the mitochondrial intermembrane space
to cytosol [65].
p53AIP1 (p53-regulated apoptosis-inducing protein 1),
NOXA (Latin for damage), and PUMA (p53 upregulated
modulator of apoptosis), which were included in BH-3
domain-containing mitochondrial Bcl2 family, were direct
transcriptional target gene products of p53 [22, 34–36].
For p53AIP1, DNA damage-mediated induction of p53AIP1
was tightly associated with p53-dependent apoptotic cell
death and phosphorylation of p53 at Ser-46. Matsuda et
al. described that p53AIP1 promotes downregulation of
the mitochondrial membrane potential through the direct
interactionwith Bcl2andinducestherelease ofcytochromec
[66].
NOXA has been rediscovered in a diﬀerential dis-
play approach [67]. Forced expression of NOXA induced
cytochrome c release from mitochondria followed by subse-
quent caspase activation, and cells underwent apoptotic cell
death. The intact BH 3 domain of NOXA was required for
the induction of apoptotic cell death.
PUMA has been identiﬁed by using a microarray anal-
ysis [68, 69]. PUMA was induced in response to ADR
(adriamycin), and p53-responsive element was found within
intron 1 of PUMA gene. Indeed, PUMA was one of the
transcriptional target genes of p53. PUMA was localized
to mitochondria and induced apoptotic cell death. Like
p53AIP1, PUMA interacted with Bcl2 and functioned to
inducecytochromecrelease,therebyactivating caspase9and
3. Jeﬀers found that BAX is required for PUMA-mediated
apoptotic cell death, placing BAX downstream of PUMA
[70].4 Journal of Biomedicine and Biotechnology
4.StabilityControlofp53
Steady-state expression level of the endogenous p53 is main-
tained at extremely low level, keeping this dangerous protein
in an inactive state. The expression level of p53 is dependent
on a balance between protein production and degradation.
It has been well-documented that p53 is rapidly induced
at protein level in response to a variety of cellular stresses
such as DNA damage [22, 34–36]. This accumulation is
largelyduetoasigniﬁcantincreaseinitsproteinstability.The
proteolytic degradation of p53 was mediated by the physical
interaction between p53 and oncogenic MDM2 [60–62].
MDM2, which is a RING-ﬁnger type E3 ubiquitin protein
ligase, bound to NH2-terminal transactivation domain of
p53, ubiquitylated COOH-terminal 6 Lys residues (Lys-
370, Lys-372, Lys-373, Lys-381, Lys-382, and Lys-386), and
thereby targeting p53 for proteasome-dependent degrada-
tion [71]. MDM2 masked NH2-terminal transactivation
domain of p53 and thereby inhibiting its transcriptional
activity [72]. A small compound termed Nutlin, which
bound to p53-binding pocket of MDM2, inhibited the
interaction between p53 and MDM2, and thereby stabilizing
p53 followed by activation of p53-dependent proapoptotic
pathway [73]. Thus, this small compound might provide a
novel strategy for cancer therapy.
In general, polyubiquitin chains target proteins to pro-
teasome and initiate the process of proteolytic degradation.
Recently, Kulikov et al. found that MDM2 associated with
several subunits of proteasome, suggesting that MDM2
might promote not only the ubiquitylation of p53 but also
recruit the ubiquitylated forms of p53 into proteasome
[74]. In addition to MDM2, RING-ﬁnger type E3 ubiqui-
tin protein ligases Pirh2 (p53-induced RING H2 domain
protein) [75] and COP1 (constitutive photomorphogenic 1)
[76] also interacted with p53 and mediated the ubiquitin-
/proteasome-dependent degradation of p53. As expected, all
of them inhibited transcriptional as well as proapoptotic
function of p53. Since MDM2, Pirh2, and COP1 were
p53-induced target gene products, they participated in
a negative autoregulatory feedback loop which controls
p53. Alternatively, p53-interacting protein termed HAUSP
(herpes virus-associated ubiquitin-speciﬁc protease) had
an intrinsic enzymatic activity to deubiquitylate p53 and
thereby increasing its stability [77].
5.PosttranslationalModiﬁcation
The induction and activation of p53 in response to cel-
lular stresses have been shown to be largely regulated at
posttranslational level through multiple mechanisms. Upon
cellular stresses, p53 is phosphorylated at Ser-15, Ser-20,
and Ser-46 [22, 34–36]. NH2-terminal phosphorylation of
p53 converted p53 from latent form to active and stable
one. On the other hand, protein phosphatases PP-1 and
PP2A had an ability to dephosphorylate p53 and negatively
modulated its activity [78, 79]. Ser-15 was phosphory-
lated by ATM (ataxia-telangiectasia mutated) [80], ATR
(ataxia-telangiectasia mutated and Rad3-related) [81], Chk1
(checkpoint kinase 1) [82], and DNA-PK (DNA-dependent
protein kinase) [83]. Ser-20 was phosphorylated by Chk2
(checkpoint kinase 2) [84] and Plk3 (polo-like kinase 3)
[85]. In addition, HIPK2 (homeodomain interacting protein
kinase 2) and PKCdelta (protein kinase C delta) have been
considered to be involved in phosphorylation of p53 at
Ser-46 [86, 87]. As mentioned above, MDM2 bound to
NH2-terminal transactivation domain of p53 to destabilize
and also inactivate p53. Stress-induced NH2-terminal phos-
phorylation of p53 promoted the dissociation of MDM2
from MDM2/p53 complex and led to the stabilization and
activation ofp53 [22, 34–36]. Alternatively,COOH-terminal
region of p53 was also phosphorylated. For example, CKII
(Casein kinase II) phosphorylated p53 at Ser-392 [88], and
PKC phosphorylated p53 at Ser-371, Ser-376, and Ser-378
[89].These COOH-terminalphosphorylations enhanced the
sequence-speciﬁc DNA-binding activity of p53 [22, 34–36].
It has been shown that COOH-terminal region of p53
acts as a negative regulator and might mask its sequence-
speciﬁc DNA-binding domain in a latent conformation [90,
91]. It is likely that phosphorylation of COOH-terminal
region of p53 might lead to a conformational shift that
enables p53 to bind more eﬃciently to its target motif,
and thereby enhancing its sequence-speciﬁc transactivation
function. In contrast, Plk11 (polo-like kinase 1) inhibited
t r a n s c r i p t i o n a la sw e l la sp r o a p o p t o t i cf u n c t i o nt h r o u g h
physical interaction and phosphorylation [92]. Therefore,
phosphorylation of p53 does not always act as an activation
signal.
In addition to stress-induced phosphorylation of p53,
p53 was subjected to the extensive acetylation mediated by
p300 with intrinsic histone acetyltransferase activity [93].
p300 which acts as a ubiquitous transcriptional coactivator,
bound to NH2-terminal region of p53 and promoted its
acetylation of a cluster of COOH-terminal Lys residues (Lys-
370, Lys-372, Lys-373, Lys-392, and Lys-381) [37]. PCAF
(p300/CBP-associated factor), another histone acetyltrans-
ferase, had an ability to acetylate Lys-320 of p53 [94].
Intriguingly, theses COOH-terminal Lys residues were the
sites for ubiquitin ligation. It is likely that p53 acetylation
catalyzed by p300 reduces its ubiquitylationlevelsby compe-
tition between acetylation and ubiquitylation. Thus, p300-
mediated acetylation of p53 increased the stability of p53
and enhanced the transcriptional as well as proapoptotic
activity of p53 [95]. Consistent with this notion, SIRT1
(Silent mating type information regulation 2 homolog 1),
which has an intrinsic deacetylase activity, interacted with
p53 and attenuated p53-dependent cell cycle arrest as well
as apoptotic cell death in response to DNA damage through
deacetylation of Lys-382 [96].
Kawai et al. described that p300 has a dual role in the
regulation of p53 stability [97]. According to their results,
p300 acted as a positive regulator to increase p53 stability
in the presence of lower level of MDM2, whereas p300
became a negative regulator for p53 to induce MDM2-
dependent degradation in the presence of higher level of
MDM2. Surprisingly, Grossman et al.found that, in addition
tohistone acetyltransferase activity, p300hasan E4ubiquitin
protein ligase activity which catalyzes polyubiquitylation of
monoubiquitylated precursor p53 [98].Journal of Biomedicine and Biotechnology 5
Sumoylation is the other type of posttranslational mod-
iﬁcation. SUMO (SUMO-1, SUMO-2, and SUMO-3) was
a ubiquitin-related small protein which covalently binds to
substrates through a mechanism similar to ubiquitylation.
PIAS (protein inhibitor of activated STAT) family acted
as a SUMO E3 ligase for p53 [99]. Unlike ubiquityla-
tion, the modiﬁcation by SUMO-1 did not target proteins
for proteolytic degradation. Previous studies suggest that
sumoylation targets p53 to the nucleoli, and sumoylated
p53 tightly binds to chromatin structure. Sumoylation of
p53 at Lys-386 resulted in a loss of a sequence-speciﬁc
DNA-binding ability and thus inhibited its transcriptional
activity, although sumoylated p53 bound to coactivator
p300 [100].
Previously, Jackson and Tjian demonstrated that O-
linked glycosylation enhances the sequence-speciﬁc tran-
scriptional activity of Sp1 [101]. Close inspection of the
amino acid residues of wild-type p53 revealed that there
exists a putative O-linked glycosylation site within the
COOH-terminal basic region. Shaw et al. described that O-
linked glycosylation enhances sequence-speciﬁc transcrip-
tional activity of p53, which might be due to the dis-
ruption of intramolecular interaction between the COOH-
terminal inhibitory domain and sequence-speciﬁc DNA-
binding domain [102].
6.TranscriptionalRegulation
As described above, p53 is largely regulated at protein
level through chemical modiﬁcations such as phosphory-
lation and acetylation. On the other hand, p53 expression
is also regulated at transcriptional level in some cases.
Previously, Reich and Levine found that p53 is transcrip-
tionally regulated in response to mitogen stimulation and
serum starvation [103]. Bruno et al. reported that p53 is
transactivated in response to anticancer drug ADR [104].
Raman et al. described that homeobox protein HOXA5 acts
as a transcriptional activator for p53 [105]. In addition,
Noda et al. identiﬁed the cis-acting element termed PE21
at a nucleotide position from −79 to −60 (relative to the
ﬁrst transcriptional initiation site) within the p53 promoter
region responsible for p53 g e n eb a s a la sw e l la si n d u c i b l e
expression in response to UV [106].
Recently, we have found that AMPK (AMP-activated
protein kinase), which acts as an intracellular energy sensor
by monitoring cellular energy levels, plays an important
role in the regulation of apoptotic cell death in response
to glucose deprivation [107]. According to our results, the
activated form of AMPK was closely involved in the tran-
scriptional activation of p53 under low glucose conditions.
It has been shown that the activation of AMPK aﬀects the
gene expression, suggesting that AMPK itself and/or AMPK-
containing cellular complex might have a transactivation
potential [108]. Subsequent studies demonstrated that there
exists a putative AMPK-responsive element within the
genomic sequence between −531 and −239 relative to the
transcriptional initiation site of p53. Within this region,
we have found out canonical CREB- (cAMP-responsive
element-binding protein-) binding site (5 -ATTACGGAA-
3 ). Finally, we have shown that AMPK collaborates with
CREB through CREB-binding site to transactivate p53 in
response to energetic stress [109]. Therefore, in addition
to posttranslational modiﬁcation, p53 is transcription-
ally regulated in response to a certain subset of cellular
stresses.
7.Subcellular Localization
Appropriate subcellular localization is critical for regulating
function of p53. p53 acts as a sequence-speciﬁc transcrip-
tion factor in cell nucleus. In addition to the mutational
inactivation of p53, the abnormal cytoplasmic localization
of p53 resulted in loss of function of p53. In contrast to
the other human tumors, p53 was rarely mutated in human
neuroblastoma [110]. Moll et al. found that wild-type p53
is detectable in cytoplasm of the majority of undiﬀerentiated
neuroblastoma, suggesting thattheinability ofnuclear access
of p53 attenuates its tumor suppressor activity [111]. Sub-
sequent study demonstrated that this abnormal cytoplasmic
localizationofwild-typep53isduetothehyperactivenuclear
export of p53 through the exposure of highly conserved
COOH-terminal NES [112]. Intriguingly, Becker et al.
described that the hyperubiquitylation of p53 contributes
to its aberrant cytoplasmic retention in neuroblastoma in
association with the impaired interaction between p53 and
HAUSP which catalyzes the deubiquitylation of p53 [113].
In addition, MDM2 had an ability to signiﬁcantly enhance
nuclear export of p53 through its COOH-terminal NES
[114].
By using an aﬃnity puriﬁcation strategy, Nikolaev et al.
discovered a large cytoplasmic protein termed Parc (p53-
associated,Parlin-likecytoplasmicprotein),whichassociated
with cytoplasmic p53 [115]. According to their results, NH2-
terminal region of Parc interacted with the COOH-terminal
region of p53. Parc had an intrinsic E3 ubiquitin ligase
activity; however, Parc had an undetectable eﬀect on the
steady-state expression level of p53. Importantly, Parc was
associated with the majority of cytoplasmic p53 and acted
as a cytoplasmic anchor protein for p53. Indeed, depletion
of Parc promoted nuclear localization of p53 and induced
p53-dependent apoptotic cell death in neuroblastoma cells.
Recently, it has been shown that the introduction of the
COOH-terminal peptide of p53 containing Parc-interacting
region disrupts the interaction between p53 and Parc in
cytoplasm and results in the nuclear relocalization of p53
[116]. The treatment of this small peptide in cancerous
cells increased the sensitivity of cancerous cells to anti-
cancer drug and enhanced p53-dependent proapoptotic
pathway.
It is worth noting that, in response to genotoxic stress,
a certain fraction of p53 translocates to mitochondria,
where p53 collaborates with BclXL and Bcl2 to induce
permeabilization ofthe outermitochondrial membrane, and
thereby releasing cytochrome c [117]. Further study revealed
that MDM2-mediated monoubiquitylation of p53 promotes
the recruitment of p53 to mitochondria in which p536 Journal of Biomedicine and Biotechnology
undergoes a rapid deubiquitylation catalyzed by mitochon-
drial HAUSP, generating nonubiquitylated proapoptotic p53
[118]. Thus, targeting p53 to mitochondria, which resulted
in the dysfunction of mitochondria, might be one of the
transcription-independent proapoptotic pathways mediated
by p53.
8.VariantFormsofp53
Yin et al. detected full-length wild-type p53 and another
p53 with a relative molecular mass of 47KDa termed
p53/47 [119]. p53/47 was detectable by the 421 monoclonal
antibody which recognized COOH-terminal portion of p53
andalsodetectablebythe1801antibodywhichrecognizedan
epitopebetweenamino acidresidues46 and55. Ontheother
hand, the DO-1 (amino acid residues 20–25) and the DO-
13 (amino acid residues 26–35) failed to recognize p53/47.
Subsequent study demonstrated that p53/47 is generated
from the NH2-terminal alternative initiation site (Met-
40). Since p53/47 lacked an NH2-terminal MDM2-binding
domain, it was not targeted for proteasome-dependent
degradation by MDM2. Previous studies indicate that NH2-
terminal transactivation domain of p53 is divided into two
independent domains such as TA 1 (amino acid residues
1–40) and TA II (amino acid residues 43–63) [120, 121].
p53/47 lacked TA I domain but contained TA II domain.
Of note, p53/47 failed to transactivate p21WAF1 but was able
to induce the transcription of MDM2, GADD45, and BAX.
These observations suggest that TA I and TA II domains
contribute to enhance the speciﬁcity of p53-target promoter
usage [119].
In addition to the alternative translation product of
p53, Bourdon et al. found the presence of multiple variant
forms of p53 arising from alternative promoter usage and
alternative splicing events [122]. Based on their results,
they identiﬁed the alternative promoter located within
intron 4, and mRNA transcribed from this internal pro-
moter generated NH2-terminally truncated form of p53
initiated at codon 133 (Δ133p53), which lacked NH2-
terminal transactivation domain and Pro-rich domain.
Further studies demonstrated that the alternative splic-
ing of intron 9 results in the generation of p53β and
p53γ, which deleted the COOH-terminal oligomerization
domain. Thus, p53 is expressed as multiple variants includ-
ing p53, p53β,p 5 3 γ, Δ133p53, Δ133p53β, Δ133p53γ,
Δ40p53, Δ40p53β,a n dΔ40p53γ. Δ40p53 corresponds to
p53/47 (Figure 2).
Immunostaining experiments revealed that most of
these p53 variants were localized largely in cell nucleus,
whereas p53γ was detectable both in cell nucleus and
cytoplasm. Additionally, Δ133p53γ was localized exclusively
in cytoplasm. p53 variants had an ability to bind diﬀer-
entially to p53-responsive promoters and modulated p53-
target gene expression. For example, p53β bound pref-
erentially to BAX and p21WAF1 promoters rather than
MDM2 promoter, whereas p53 bound preferentially to
p21WAF1 and MDM2 promoters than to BAX promoter
[122].
TA DB OD
p53
p53β
p53γ
Δ40p53
Δ40p53β
Δ40p53γ
Δ133p53
Δ133p53β
Δ133p53γ
Figure 2: Schematic diagram of p53 variants. TA: transactiva-
tion domain; DB: sequence-speciﬁc DNA-binding domain; OD:
oligomerizationdomain.
9.DNA Damage Response
During the early phase of DNA damage response, the
activated forms of ATM (phospho-ATM at Ser-1981) phos-
phorylated histone variant H2AX at Ser-139 (γH2AX). This
phosphorylation eventtookplaceata largechromatin region
surrounding DNA lesions and formed the nuclear foci, sug-
gestingthatγH2AXactsasasensitivemarkerforthepresence
ofDNAdamage[123–125].ThedisruptionofH2AXresulted
in an induction of genome instability and DNA double-
strand break repair defects [126]. Then, NFBD1/MDC1
(nuclear factor with BRCT domain 1/mediator of DNA
damage checkpoint protein 1), which had an antiapoptotic
potential [127], interacted directly with γH2AX through
its COOH-terminal BRCT domains and recruited MRN
(MRE11, Rad50, and NBS1) complex onto the sites of DNA
damage to facilitate the eﬃcient DNA repair [128–130].
γH2AX then served as a platform for the recruitment of
DNA checkpoint signaling factors as well as multifunctional
MRN complex. Therefore, NFBD1-mediated local accumu-
lation of DNA repair machinery such as MRN complex at
the chromatin regions ﬂanking the sites of DNA damage
contributedto an increase in the ﬁdelity of genomicintegrity
in response to DNA damage. Indeed, NFBD1-deﬁcient mice
exhibited chromosome instability, DNA repair defects, and
radiation sensitivity [131]. In response to DNA damage, cell
cycle checkpoint was activated to arrest cells at G1 phase,
giving them time to repair damaged DNA. Recently, we
have found that, during the early phase of DNA damage
response, NFBD1 binds to NH2-terminal region of p53 to
inhibit ATM-mediated p53 phosphorylation at Ser-15, and
thereby blocking its proapoptotic activity [132]. During the
late phase of DNA damage response, the expression level
of NFBD1 is sharply downregulated, and then the activated
forms of ATM phosphorylate free p53 at Ser-15 to enhance
its proapoptotic activity [132].
Runt-related (RUNX) gene family is composed of three
members including RUNX1, RUNX2, and RUNX3 [133].
Among them, RUNX3 has been considered to be a candidate
tumor suppressor for human gastric cancer [134]; however,
it remains unclear how RUNX3 exerts its tumor suppressor
function. Recently, we have found that, in response to ADRJournal of Biomedicine and Biotechnology 7
treatment, RUNX3 is induced to accumulate in cell nucleus
and binds to p53 [135]. Based on our results, RUNX3
acted as a coactivator for p53 to enhance its transcriptional
and proapoptotic activities. Of note, knocking down of the
endogenous RUNX3 signiﬁcantly repressed ADR-mediated
phosphorylation of p53 at Ser-15. Since RUNX3 had an
abilitytointeractwithactivatedformsofATM,itislikelythat
RUNX3recruitstheactivated formsofATM tolatentformof
p53 and thereby assisting ATM-dependent phosphorylation
of p53 at Ser-15 in response to ADR. Thus, RUNX3is closely
involved at least in part in the regulation of DNA damage-
mediated activation of p53 (Figure 3).
10.p53Family
p53 tumor suppressor family is composed of three members
including p53, p73 and p63. Like p53, p73, and p63 act as
sequence-speciﬁc nuclear transcription factors and induce
cell cycle arrest and/or apoptotic cell death in response
to a certain subset of cellular stresses. p73 is expressed as
multiple splicing variants with diﬀerent COOH-terminal
structures arising from thealternativesplicing oftheprimary
transcript such as p73α,p 7 3 β,p 7 3 γ,p 7 3 δ,p 7 3 ε,a n dp 7 3 ζ
(37, 40, 135). Since all of them contain an intact NH2-
terminal transactivation domain, they have an ability to
transactivate the overlapping set of p53-target gene (TA
variants). Intriguingly, p73 encodes the NH2-terminally
truncatedvariants termedΔNp73[136]. SinceΔNp73lacked
theintact NH2-terminal transactivation domain,ΔNp73was
the transactivation defective and acted as the dominant-
negative inhibitor toward TAp73 and wild-type p53 [136].
In this connection, ΔNp73 had an oncogenic potential
[137]. Additionally, mutant forms of p53 inhibited the
transcriptional and proapoptotic activities of TAp73 [138].
Of note, we and others demonstrated that TAp73 induces
the transcription of its own inhibitor ΔNp73, creating
a dominant-negative feedback loop which regulates the
proapoptotic activities of both TAp73 and wild-type p53
[139–141]. Similarly, p63 encodes TAp63 and ΔNp63 [39].
Therefore, relative ratio of TA and ΔN variants might be an
important determinant of the cell fate.
Since p73 and p63 induce apoptotic cell death in
cancerouscells, extensivemutationsearches wereperformed.
Inasharp contrasttop53,p73andp63wererarely mutatedin
various human tumor tissues [142], suggesting that p73 and
p63 might not be classical Knudson-type tumor suppressors.
Initial genetic studies revealed that p73-deﬁcient mice and
also p63-deﬁcient mice do not develop spontaneous tumors
[143–145]. Instead, p73-deﬁcient mice displayed severe
developmental defects including hydrocephalus, hippocam-
pal dysgenesis, and abnormal pheromone sensory pathways.
In p63-deﬁcient mice, diﬀerentiation of apical ectodermal
ridge failed, and generation of skin was not observed. These
resultssuggest that p73as well as p63playsan important role
in normal development. Strikingly, it has been shown that
p73 and p63 heterozygous mice develop malignant tumors
at high frequency. Tumors derived from these mice exhibited
loss of the remaining wild-type allele at high frequency.
DNA damage
RUNX3
ATM
P Ser-1981
RUNX3 p53
P Ser-15
BAX PUMA
Apoptosis
Figure 3 :R U N X 3a c t sa sac o a c t i v a t o rf o rp 5 3i nr e s p o n s et oD N A
damage. In response to DNA damage, RUNX3 collaborates with
activated form of ATM and induces phosphorylation of p53 at Ser-
15. Phosphorylated form of p53 transactivates proapoptotic BAX
and PUMA.
DNA damage
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Figure 4: Upon DNA damage, activated form of ATM phosphory-
lates IKK-α and promotes nuclear accumulation of IKK-α. IKK-α
enhances transactivation as well as proapoptotic function of p73 in
a p53-independent manner.
These observations strongly suggest that loss of p73 and/or
p63 function causes tumor development [146].
p73 and p63 are regulated at transcription as well as
posttranslation levels. It has been shown that there exist
several E2F1-binding sites within p73 promoter region, and
E2F1 actually acts as a transcriptional activator for p73
[147–149]. Recently, Logotheti et al. demonstrated that Sp1
binds to the external promoter of p73 gene and induces the
expressionofp73[150].Ontheotherhand,Fontemaggietal.8 Journal of Biomedicine and Biotechnology
found that ZEB(zinc ﬁnger/homeodomain repressor) acts as
a transcriptional repressor for p73 [151]. Of note, we have
described that TATA-binding protein- (TBP-) like protein
(TLP) has an ability to directly transactivate p63 [43].
Like p53, the activity and stability of p73 and p63 is
regulated by chemical modiﬁc a t i o n ss u c ha sp h o s p h o r y -
lation. c-Abl-dependent phosphorylation of p73 at Tyr-99
resulted in an increase in its stability [152–154]. PKCδ
phosphorylated p73 at Ser-289 to enhance its transcrip-
tional activity [155]. Chk1-mediated phosphorylation of
p73 at Ser-47 resulted in an enhancement of its tran-
scriptional activity [156]. Recently, we have found that,
in response to cisplatin (CDDP), IKK-α (IκBk i n a s e - α)i s
induced to be accumulated in cell nucleus and interacts
with p73 to increase its stability, thereby enhancing its
proapoptotic activity in a p53-independent manner [157,
158]. IKK-α had an ability to phosphorylate the NH2-
terminal portion of p73 (Figure 4). On the other hand,
CDK-mediated phosphorylation of p73 led to a signiﬁcant
inhibition of its transcriptional activity [159]. In addition,
we have demonstrated that p73 is strongly inhibited by
Plk1 through physical interaction and phosphorylation at
Thr-27 [160]. Therefore, phosphorylation of p73 might not
always act as an activation signal. Similarly, we have found
that p63 is inhibited by Plk1-mediated phosphorylation
at Ser-52 [161].
Since p73 and p63 were rarely mutated in human
tumors, elucidation of the precise regulatory mechanisms
behind DNA damage-induced activation of p73 and p63
might provide a clue to develop a novel strategy for
the treatment of malignant tumors bearing nonfunctional
p53.
11.FuturePerspective
p53 plays a pivotal role in the regulation of cell fate
determination in response to a variety of cellular stresses.
Dysfunction of p53 such as mutational inactivation per-
mits the abnormal cell growth and ﬁnally results in
the malignant tumor development. In addition, loss of
function of p53 contributes to the signiﬁcant decrease
in the sensitivity of tumor cells to anticancer drugs.
Therefore, the elucidation of the precise molecular mech-
anisms behind stress-induced activation of p53 might
provide a clue(s) to ﬁnd out the attractive therapeu-
tic target(s) for cancer treatment. In contrast to p73
and p63, p53 is frequently mutated in human tumors.
Mutant forms of p53 lack their proapoptotic function
and display a dominant-negative behavior toward wild-
type p53 family. Further eﬀorts should be required to
develop the novel strategies and/or the chemical com-
pounds which could convert the abnormal conformations
of mutant p53 to normal ones. In this connection, one
of the remaining questions is that why p53 is frequently
mutated in tumor tissues. Although it could be due to
the serious defects in the DNA repair machinery in these
tumors, further studies should be required to address this
issue.
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